Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -2364.8%. (2018–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $47224 | $40M | $94M | $182M | $1.0B | — | — | — |
| Enterprise Value | $-1465833 | $39M | $85M | $163M | $968M | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 48.44 | 10.99 | 26.80 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -2364.8% | -2364.8% | -164.1% | -79.4% | -73.0% | — | — | — |
| ROA | -215.8% | -215.8% | -103.7% | -72.4% | -60.7% | -1752.5% | -6341.1% | -4294.2% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | -2367.3% | -2367.3% | -169.5% | -80.8% | -70.1% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -4.73 | -1.15 | -0.98 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -115.31 | -115.31 | — | — | -128.88 | -28.34 | -25.53 | -175.34 |
Net cash position: cash ($2M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.63 | 0.63 | 1.25 | 6.36 | 18.96 | 0.02 | 0.02 | 0.05 |
| Quick Ratio | 0.63 | 0.63 | 1.25 | 6.36 | 18.96 | 0.02 | 0.02 | 0.05 |
| Cash Ratio | 0.61 | 0.61 | 1.19 | 6.14 | 17.65 | 0.01 | 0.01 | 0.04 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $4M | $1M | $1M | $1M | $494515 | $521515 | $5M |
Imminent liquidity exhaustion risk
According to recent SEC filings, the company's current ratio has deteriorated sharply from 6.36 in 2022Q4 to a precarious 0.63 in 2024Q4, signaling that liquid assets are now insufficient to cover short-term obligations and highlighting a severe risk to the firm's ongoing ability to fund research.
The rapid decline in the current ratio suggests that the company has exhausted its primary liquidity buffers, leaving it highly dependent on external financing to meet immediate liabilities. Investors should monitor the potential for further dilution or operational scaling back, as the current cash position appears inadequate to sustain the development pipeline through the next clinical milestone.
As reported in financial statements, the company maintains a consistently negative profitability profile, with ROA plummeting to -3.6% in 2024Q4, which underscores the absence of commercial revenue and the persistent drain of high fixed R&D costs on the firm's limited capital base.
The lack of gross or operating margins confirms that the business is currently a pure research entity rather than a commercial enterprise. This negative profitability is structural, and any improvement in these metrics would require a fundamental shift toward licensing or royalty-based revenue streams that are not yet present in the current financial data.
Based on historical financial filings, the company's return on equity has remained deeply negative, reaching -108.1% in 2023Q4, which indicates that the firm is currently destroying shareholder capital as it attempts to advance its proprietary delivery platforms without generating any offsetting commercial returns.
The inability to generate positive returns on invested capital is a direct consequence of the high-burn, preclinical business model. Without a clear path to clinical validation, the current trend suggests that capital allocation is primarily focused on survival rather than compounding value, which warrants extreme caution for long-term investors.
As indicated by market data, the use of P/E or EV/EBITDA ratios is fundamentally inappropriate for Virpax, as these metrics obscure the company's status as a pre-revenue entity where value is derived from pipeline probability rather than current earnings or cash flow generation.
Investors should instead focus on probability-adjusted net present value (rNPV) of the pipeline and the remaining cash runway relative to the burn rate. Applying standard valuation multiples to a firm with no revenue and negative equity leads to misleading conclusions that ignore the binary nature of clinical development risks.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VRPX stock.
Virpax Pharmaceuticals, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Virpax Pharmaceuticals, Inc.'s return on equity (ROE) is -2364.8%. The historical average is -105.5%.
Based on historical data, Virpax Pharmaceuticals, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.